Symbiotec Pharmalab IPO Subscription Reaches 6.24x on Day 4; NII Subscription at 14.96x 

Mumbai, August 27: The Symbiotec Pharmalab IPO is seeing steady demand as the issue enters the final hours of bidding. The ₹1,757 crore IPO opened on August 24 and is scheduled to close today, August 27, 2026.

As of 10:45 AM on August 27, investors had placed bids for 7,77,97,200 shares, compared with 1,24,60,533 shares available in the public portion. This took the overall subscription to 6.24 times. The issue had received 21,20,413 applications by the time of the latest update.

The NII segment is currently driving the subscription numbers, while retail investors and employees have also put in bids well above their respective quotas. QIB participation, on the other hand, remains below the full issue size so far. 

NII Category Leads Subscription at 14.96x 

The NII portion has attracted the strongest demand so far, with subscription reaching 14.96 times.

Looking closer at the category, the sNII portion has been subscribed 16.52 times, while the bNII portion stands at 14.19 times.

Retail investors have also shown healthy interest. The retail portion is subscribed 5.71 times, with bids received for 3,55,03,590 shares against 62,13,562 shares reserved for the category.

The employee portion has received 6.64 times subscription, with bids for 2,21,805 shares against 33,408 shares on offer.

The QIB (Ex Anchor) portion is currently at 0.63 times, with bids for 22,20,990 shares against 35,50,608 shares available. 

Day-wise Subscription Details 

The issue had a relatively slow start, ending Day 1 at 0.85x subscription. Activity picked up on Day 2, taking the overall figure to 1.95x.

Demand really accelerated on Day 3. By the end of August 26, the IPO had reached 5.62x subscription, with the NII segment becoming the clear standout.

On the final day, the overall subscription has moved up to 6.24x so far. NII demand has climbed from 12.86x to 14.96x, while retail subscription has edged up from 5.38x to 5.71x. 

Symbiotec Pharmalab IPO Details 

The Symbiotec Pharmalab IPO comes with a price band of ₹938 to ₹988 per share. The issue price is ₹988 per share, while the minimum lot size is 15 shares.

At the upper end of the price band, a retail investor needs ₹14,820 to apply for one lot. 

The ₹1,757 crore issue consists of: 

• Fresh Issue: 15,21,261 shares worth up to ₹150 crore 

• Offer for Sale: 1,62,65,181 shares worth up to ₹1,607 crore 

• Total Issue Size: 1,77,86,442 shares 

Of the net issue, 50% is reserved for QIBs, 15% for NIIs and 35% for retail investors.

The IPO also has a separate employee reservation of 33,408 shares. Eligible employees are being offered a ₹90 discount to the issue price. 

Symbiotec Pharmalab IPO Anchor Investors 

Before the public issue opened, Symbiotec Pharmalab raised ₹526.20 crore from anchor investors.

The anchor bidding was completed on August 21, 2026, with 53,25,909 shares allotted to anchor investors.

The lock-in period for 50% of these shares is scheduled to end on September 27, 2026. The remaining anchor shares will have a longer lock-in period ending on November 26, 2026.

What Happens After the IPO Closes? 

The Symbiotec Pharmalab IPO is still open for subscription as of the latest update and will close on August 27.

Once the bidding window shuts, investors will turn their attention to the allotment. The tentative schedule is as follows: 

Investors who are allotted shares are expected to see them credited to their demat accounts on August 31. Refunds for unsuccessful applications are also expected around the same date.

The company is scheduled to list on September 1, 2026, on both the NSE and BSE.

About Symbiotec Pharmalab Ltd. 

Symbiotec Pharmalab Ltd., incorporated in 2002, operates in the pharmaceutical and biotechnology industry. The company focuses on the development and manufacture of active pharmaceutical ingredients (APIs), nutritional ingredients and specialty products.

Over the years, the company has expanded from a lab-scale steroidal hormone API manufacturer into a larger, backward-integrated manufacturing business. It serves customers across India as well as international markets.

Its manufacturing and regulatory capabilities include approvals and certifications from authorities such as the US FDA and EU-GMP, along with regulatory bodies in India, Korea and other markets. 

Conclusion 

The Symbiotec Pharmalab IPO has reached 6.24x subscription on its final day of bidding, based on data available at 10:45 AM on August 27.

The NII category continues to lead the issue with 14.96x subscription, followed by employees at 6.64x and retail investors at 5.71x. QIB demand is currently at 0.63x.

With the IPO set to close today, the next key dates for investors are the August 28 allotment and the proposed September 1 listing on the NSE and BSE.  

Source: 

• https://www.nseindia.com/market-data/issue-information?symbol=SYMBIOTEC&series=EQ&type=Active